Neoadjuvant Chemotherapy Therapy News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Neoadjuvant Endocrine Therapy Can Be Helpful in Breast CancerNeoadjuvant Endocrine Therapy Can Be Helpful in Breast Cancer
In women with localized estrogen receptor-positive breast cancer, neoadjuvant endocrine therapy - even as monotherapy - prompts response rates similar to those of combination chemotherapy but with lower toxicity, according to a meta-analysis by U.S. researchers. Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - July 7, 2016 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Revisiting Neoadjuvant Hormones for ER+ Breast Cancer (CME/CE)
(MedPage Today) -- Improved response, breast-conservation rates versus chemotherapy (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 3, 2016 Category: Hematology Source Type: news

ERCC2 validated as chemotherapy response biomarker in bladder cancer
Somatic mutations in the helicase-encoding ERCC2 gene are associated with response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive urothelial bladder carcinoma. (Source: MedWire News)
Source: MedWire News - June 17, 2016 Category: Consumer Health News Tags: Oncology Source Type: news

PAN-EX supports neoadjuvant chemotherapy in high-risk rectal cancer
Patients with high-risk, locally advanced rectal cancer could benefit from neoadjuvant chemotherapy before undergoing chemoradiotherapy, suggest the results of a pooled analysis. (Source: MedWire News)
Source: MedWire News - June 1, 2016 Category: Consumer Health News Tags: Oncology Source Type: news

FDA grants Roche’s cancer immunotherapy Tecentriq (atezolizumab) accelerated approval for people with a specific type of advanced bladder cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Tecentriq® (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-based chemotherapy, or whose disease has worsened within 12 months of receiving platinum-based chemotherapy before surgery (neoadjuvant) or after surgery (adjuvant). Urothelial carcinoma accounts for 90% of all bladder cancers and can also be found in the renal pelvis, ureter and urethra. (Source: Roche Media News)
Source: Roche Media News - May 19, 2016 Category: Pharmaceuticals Source Type: news